Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensCell Lines for BBB Modeling
- Immortalized Cells for BBB ModelingPrimary Cells for BBB ModelingStem Cells for BBB ModelingProteins & Peptides for Stroke ResearchOnline Inquiry
Brilliant Blue G (AC153)
Cat.#: ASSD-153
Specifications
Description Brilliant Blue G is a type of non-competitive P2X7 antagonist (IC50 values are 10 and 200 nM at rat and human P2X7 respectively). The compound displays neuroprotective and anti-inflammatory properties. It is also a protein-binding dye, causing a color change from red to blue. Synonyms Acid blue 90; Coomassie Brilliant Blue G; NSC 328382; CBBG Size 1g Chemical Name Coomassie Brilliant Blue G (CBBG) Molecule Weight 854.02 Molecular formula C47H48N3NaO7S2 CAS Number 6104-58-1 PubChem identifier 6324599 Solubility Soluble in water (40mg/ml, at 20°C) or methanol Storage RT Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-146 Pyronin Y (AC146) 1 g, 5g inquiry ASSD-210 7-Amino-4-methyl-3-coumarinacetic acid N-succinimidyl ester (AC210) 5 mg inquiry ASSD-205 Acridinium C2 NHS Ester (AC205) 5 mg, 10 mg inquiry ASSD-220 Nitrofluorescein, Isomer 2 (AC220) 1 g inquiry ASSD-121 Fluorescent adenosine A3 antagonist [XAC] (AC121) 500 μg inquiry ASSD-228 ImmunoHistoMount (AC228) 30 ml inquiry ASSD-196 5-Carboxyfluorescein (AC196) 100 mg, 250 mg inquiry ASSD-215 1-Pyrenylmethyl Methanethiosulfonate (AC215) 10 mg inquiry ASSD-211 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester (AC211) 100 mg, 1 g inquiry ASSD-147 Rhodamine phalloidin-TRITC (AC147) 300 tests, 100μg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket